NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
IPO Year: 2016
Exchange: NASDAQ
Website: nanthealth.com
SC 13D - NantHealth, Inc. (0001566469) (Subject)
SC 13D - NantHealth, Inc. (0001566469) (Subject)
Jerry Magin, Neil Carpenter, and Arlyn Small join leadership team to drive next-level company growth NantHealth, Inc. (NASDAQ:NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the appointments of Jerry Magin as Senior Vice President of Global Sales and Marketing; Neil Carpenter as Senior Vice President of Strategy and Arlyn Small as Senior Vice President of Human Resources, to its executive leadership team. Jerry Magin has more than 25 years of industry experience building and scaling high-performing marketing, business development, sales and operational teams. In his role as Senior Vice President of Globa
NantHealth, Inc. (NASDAQ:NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the appointment of Tiffany Avery, MD, MPH, as Chief Medical Officer. In her new position, Dr. Avery will be responsible for providing clinical strategic direction and guiding the development and deployment of NantHealth's Eviti decision support platform and other innovative products and services. "Appointing Dr. Avery to our leadership team is an incredibly valuable addition to the organization, particularly as we expand into areas like population health and additional disease states for Eviti," said Ron Louks, Chief Operating Officer, NantH
4 - NantHealth, Inc. (0001566469) (Issuer)
3 - NantHealth, Inc. (0001566469) (Issuer)
3 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
3 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
4 - NantHealth, Inc. (0001566469) (Issuer)
Q3 2022 Financial and Operational Highlights: Total net revenue was $16.6 million Gross profit was $9.7 million, or 58% of total revenue The company's Eviti Connect platform earned full URAC accreditation for Health Utilization Management, through 2025 Maryland Physicians Care signed a two-year renewal agreement for Eviti Connect for Autoimmune Diseases Post quarter end: Secured 3-year contract extension with large national commercial insurer that provides coverage to more than two million Medicaid members across multiple states. Expanded contract now includes formulary redirection NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help busi
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 third quarter on Thursday, November 3, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-942-2493 from the U.S. or Canada, or 212-231-2931 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks ec
Q2 2022 Financial and Operational Highlights: Total net revenue was $16.5 million Gross margin was 55% of total revenue NantHealth products won three industry awards, one from MedTech Breakthrough and two from Spring Digital Health NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its second quarter ended June 30, 2022. "For the 2022 second quarter, we reported net revenue of $16.5 million, representing the third consecutive quarter of top-line growth," said Ron Louks, Chief Operating Officer, NantHealth. "We are pleased to note that our overall gro
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 second quarter on Thursday, August 4, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-771-6692 from the U.S. or Canada, or 212-231-2907 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks eco
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 first quarter on Thursday, May 5, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-920-5526 from the U.S. or Canada, or 212-231-2907 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks ecosyst
Q4 2021 Financial Highlights: Total revenue was $16.0 million Total gross margin was 57% Full-Year 2021 Financial Highlights: Total revenue was $62.6 million Total gross margin was 56% Operational Highlights: In Q4, signed and went live with Eviti Connect for Autoimmune Diseases program with Maryland Physician's Care (MPC), to provide digital drug authorizations for members living with autoimmune conditions In Q4, continued expansion of Eviti Connect for Oncology services provided through a key Eviti channel partner with the addition of the country's largest customer-owned health insurer In Q4, released the first OpenNMS Minion Appliance, a cloud-enabled, simple sol
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2021 fourth quarter and full year on Thursday, February 24, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 877-407-0312 from the U.S. or Canada, or 201-389-0899 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of
Q3 2021 Financial Highlights: Total net revenue was $14.4 million Gross margin was 52% Cash of $45.5 million at September 30, 2021 Operational Highlights: Signed and preparing to launch first Eviti Connect program for autoimmune disease Achieved utilization management licensure/certification in six states enabling expansion of Eviti Connect to include fully delegated services In October, signed multi-year NaviNet Open agreement with third party administration service provider with potential to deploy provider portal capabilities to multiple new self-insured health plans Also in October, signed agreement with Care Continuity allowing parties to partner on product offerings
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2021 third quarter on Thursday, November 4, 2021, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-584-1507 from the U.S. or Canada, or 212-231-2902 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks ec
Q2 2021 Financial Highlights: Total net revenue was $16.1 million Gross margin was 56% Completed $137.5 million financing transaction, extending maturity of debt and increasing cash position to $52 million at June 30 NaviNet AllPayer won Digital Health Award in Connected Digital category for enhancing digital payer transactions Post Quarter End: Announced appointment of Tiffany Avery, MD, MPH, as NantHealth's Chief Medical Officer NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its second quarter ended June 30, 2021. "Our 2021 second-quarter
15-12G - NantHealth, Inc. (0001566469) (Filer)
8-K - NantHealth, Inc. (0001566469) (Filer)
EFFECT - NantHealth, Inc. (0001566469) (Filer)
EFFECT - NantHealth, Inc. (0001566469) (Filer)
POS AM - NantHealth, Inc. (0001566469) (Filer)
POS AM - NantHealth, Inc. (0001566469) (Filer)
S-8 POS - NantHealth, Inc. (0001566469) (Filer)
S-8 POS - NantHealth, Inc. (0001566469) (Filer)
S-8 POS - NantHealth, Inc. (0001566469) (Filer)
8-K - NantHealth, Inc. (0001566469) (Filer)
HITRUST Certification validates NantHealth's commitment to aligning with key regulations and protecting sensitive information NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions transforming complex data into actionable insights, today announced its Eviti Connect solution has earned Certified status for information security by HITRUST. HITRUST Risk-based, 2-year (r2) Certified status demonstrates that NantHealth's Eviti Connect solution has met key regulations and industry-defined requirements for managing risk. This achievement places NantHealth in an elite group of organizations worldwide that have earned this certification. "Organizations like ours are under c
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the entry into a credit agreement for a new senior secured term loan in an aggregate principal amount of $22.5 million. The company intends to use the proceeds to continue funding its existing businesses and for general corporate purposes. The Term Loan Facility was funded by two existing NantHealth investors: Highbridge Capital Management, LLC and Nant Capital, LLC. "The era of digital medicine and augmented intelligence has finally arrived. NantHealth has stood at the forefront of driving evidence based, low cost care to treat
Meridian 2023 is a look into the future of network monitoring, centered around simplification The OpenNMS Group, Inc., a subsidiary of NantHealth, Inc. (NASDAQ:NH), today announced the release of OpenNMS Meridian 2023. With this major release, the fully open source Meridian product, which is the optimized and supported version of the OpenNMS platform curated by The OpenNMS Group, Inc. (OpenNMS) for production environments, now features cloud services, containerization benefits, and other advancements. "The cloud capabilities we're launching with Meridian 2023 bring us a huge step closer to our vision of a world where monitoring just happens," said David Hustace, President, Founderat OpenN
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that the company has implemented a reverse stock split at a ratio of 1-for-15, which is expected to be effective 5 p.m. Eastern Time (ET) on December 15, 2022. The company's common stock is expected to begin trading on a split-adjusted basis at commencement of trading on Friday, December 16, 2022. The reverse stock split was approved by NantHealth's stockholders on August 18, 2022 and is intended to increase the per share trading price of the company's common stock, which the company expects will satisfy the minimum bid price requ
Q3 2022 Financial and Operational Highlights: Total net revenue was $16.6 million Gross profit was $9.7 million, or 58% of total revenue The company's Eviti Connect platform earned full URAC accreditation for Health Utilization Management, through 2025 Maryland Physicians Care signed a two-year renewal agreement for Eviti Connect for Autoimmune Diseases Post quarter end: Secured 3-year contract extension with large national commercial insurer that provides coverage to more than two million Medicaid members across multiple states. Expanded contract now includes formulary redirection NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help busi
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 third quarter on Thursday, November 3, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-942-2493 from the U.S. or Canada, or 212-231-2931 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks ec
The designation demonstrates the highest level of commitment to quality healthcare NantHealth Inc. (NASDAQ:NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced it has been granted full URAC accreditation for Health Utilization Management for its Eviti Connect platform for another three years. NantHealth's utilization management procedures have been accredited by URAC since 2010. This latest recognition extends URAC accreditation through September 1, 2025. URAC is a Washington, DC-based nonprofit organization that helps promote healthcare quality through the accreditation of organizations involved in medical c
Q2 2022 Financial and Operational Highlights: Total net revenue was $16.5 million Gross margin was 55% of total revenue NantHealth products won three industry awards, one from MedTech Breakthrough and two from Spring Digital Health NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today reported financial results for its second quarter ended June 30, 2022. "For the 2022 second quarter, we reported net revenue of $16.5 million, representing the third consecutive quarter of top-line growth," said Ron Louks, Chief Operating Officer, NantHealth. "We are pleased to note that our overall gro
NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that it will report financial results for its 2022 second quarter on Thursday, August 4, 2022, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company's performance. The conference call will be available to interested parties by dialing 800-771-6692 from the U.S. or Canada, or 212-231-2907 from international locations. The call will be broadcast via the Internet at www.nanthealth.com. About NantHealth, Inc. NantHealth, a member of the NantWorks eco
Official Release of OpenNMS Plugin API 1.0 Provides a Stable Development Ecosystem to Build Integrations and Plugins The OpenNMS Group, Inc., a subsidiary of NantHealth, Inc. (NASDAQ:NH), today announced OpenNMS Horizon 30, the latest major release of OpenNMS' popular open source network monitoring solution. With the Horizon 30 release, OpenNMS is now improving network traffic analysis by providing advanced NetFlow thresholding and centralized storage of network device configurations, among other enhanced capabilities ideal for the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005368/en/ Alongside Horizon 30,
Gainers CohBar, Inc. (NASDAQ:CWBR) shares jumped 161% to $4.05 after the company and Morphogenesis announced they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. HeartCore Enterprises, Inc. (NASDAQ:HTCR) gained 76.6% to $2.26 following better-than-expected first-quarter results. Ocean Biomedical, Inc. (NASDAQ:OCEA) shares climbed 63% to $8.57 after the company announced a patent award for novel cancer immunotherapy treatment, granted for prostate cancer, colon cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma and lung cancer. Shuttle Pharmace
Gainers CohBar (NASDAQ:CWBR) stock rose 192.9% to $4.54 during Tuesday's pre-market session. The market value of their outstanding shares is at $13.1 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 50.48% to $1.55. The market value of their outstanding shares is at $21.1 million. Biocept (NASDAQ:BIOC) shares increased by 36.43% to $6.74. The market value of their outstanding shares is at $3.9 million. Finch Therapeutics Gr (NASDAQ:FNCH) shares rose 14.39% to $0.33. The market value of their outstanding shares is at $15.7 million. Icosavax (NASDAQ:ICVX) shares moved upwards by 14.23% to $8.99. The market value of their outstanding shares is at $372.4 million. IMAC Hldgs (NASD
Gainers Trevena, Inc. (NASDAQ:TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) jumped 139% to $0.9321. Bellicum Pharmaceuticals 13D filing showed Baker Bros. Advisors reported a 19.99% active stake in the company. Immuron Limited (NASDAQ:IMRN) climbed 62.9% to $3.0470 after the company announced the FDA removed the clinical hold on the New Campylobacter ETEC Therapeutic IND application. SMX (Security Matters) Public Limited Company (NASDAQ:SMX) climbed 45.1% to $1.93 after jumping around 54% on Friday. VCI Global Limited (NASDAQ:VCIG) gained 37% to $5.37. EZFill Holdings Inc. (NASDAQ:EZFL) s
Gainers Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) gained 105.2% to $0.8001 in pre-market trading. Bellicum Pharmaceuticals 13D filing showed Baker Bros. Advisors reported a 19.99% active stake in the company. Crown ElectroKinetics Corp. (NASDAQ:CRKN) gained 81.7% to $0.1997 in pre-market trading after dropping 12% on Friday. Crown Electrokinetics recently issued a letter to shareholders. Magic Empire Global Limited (NASDAQ:MEGL) gained 37.5% to $2.49 in pre-market trading after dropping over 11% on Friday. SMX (Security Matters) Public Limited Company (NASDAQ:SMX) gained 36.8% to $1.82 in pre-market trading after jumping around 54% on Friday. Greenland Technologies Holding Corpora
Gainers Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) shares jumped 153% to $3.24 after the company announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Bioventus Inc. (NASDAQ:BVS) gained 73% to $2.53. Bioventus entered into settlement agreement with former CartiHeal shareholders regarding obligations under amended option & equity purchase agreement for prior acquisition of CartiHeal. Mount Rainier Acquisition Corp (NASDAQ:RNER) rose 25.2% to $6.32. Mount Rainier Acquisition shares dropped 46% on Monday possibly after the company's general meeting was cancelled on Sunday. Yoshiharu Global Co. (NASDAQ:YOSH
NantHealth's (NASDAQ:NH) short percent of float has risen 335.56% since its last report. The company recently reported that it has 79 thousand shares sold short, which is 3.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest
Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 50.0% to $0.12 during Monday's regular session. The current volume of 120.0K shares is 12.4% of Scopus BioPharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.5 million. NantHealth (NASDAQ:NH) shares increased by 28.55% to $3.6. The current volume of 183.6K shares is 205.1% of NantHealth's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $27.7 million. OncoCyte (NASDAQ:OCX) shares moved upwards by 27.29% to $0.38. The current volume of 1.0 million shares is 282.2% of OncoCyte's
Gainers ADC Therapeutics SA (NASDAQ:ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Energy Focus, Inc. (NASDAQ:EFOI) rose 22.1% to $0.3899 in pre-market trading after declining 11% on Tuesday. Energy Focus, last month, posted a Q3 loss of $0.29 per share. Caravelle International Group (NASDAQ:CACO) shares rose 21.8% to $2.57 in pre-market trading after dropping 57% on Tuesday. 180 Life Sciences Corp. (NASDAQ:ATNF) rose 18.8% to $2.65 in pre-market trading. 180 Life Sciences Corp shares dropped 15% on Tuesday after the company
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Avaya Holdings Corp. (NYSE:AVYA) gained 57% to $0.2384. Athenex, Inc. (NASDAQ:ATNX) surged 47% to $0.1991 after the company announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer. Verona Pharma plc (NASDAQ:VRNA) shares climbed 40.5% to $18.71 after the company announced ensifentrine met primary and key secondary endpoints in t
NantHealth's (NASDAQ:NH) short percent of float has fallen 19.27% since its last report. The company recently reported that it has 265 thousand shares sold short, which is 0.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest